logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health eyes US listing as it heads to profitability

Snapshot

  • Developer of technologies that modulate the human microbiome 
  • Targeting weight management and chronic lifestyle diseases
  • Hopes to reach profitability in 2020 
  • Mulling a NASDAQ listing 
OptiBiotix Health PLC -

Quick facts: OptiBiotix Health PLC

Price: 49.5 GBX

AIM:OPTI
Market: AIM
Market Cap: £42.29 m
Follow

So, what does it do?

OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.

With an established pipeline of microbiome modulators, the firm is working on the prevention and management of chronic lifestyle diseases such as obesity, hypercholesterolemia and lipid profiles and diabetes.

Its product roster includes weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).

How’s it doing?

It signed 23 licensing agreements last calendar year and is expecting to maintain that sort of traction this year. In all, it has 52 of these agreements and is in 24 countries.

In 2020 the commercialisation process should be provided a boost following the launch of its SlimBiome weight management range in healthcare chain Holland and Barrett and a roll-out in Italy of a product called Ezimega 3, which contains Opibiotix’s cholesterol-lowering additive.

Headed towards profitability

In a comprehensive update on trading released on January 17, Optibiotix said total sales for the 12 months ended November 30 were £808,000. Adding in £617,000 from the disposal of a small tranche of shares it owns in sister company SkinBioTherapeutics, total income was £1.43mln, up from £541,614 a year earlier.

In terms of funding, the firm had just over £1.2mln in cash and trade debtors at the year-end, or £1.4mln once R&D tax credits are recovered. It also has a £7mln stake in SkinBioTherapeutics, which would support what it termed “capital growth”.

Corporate developments

In the Jan 17 announcement, the AIM-listed firm said it was mulling a stock market listing on NASDAQ in the US. “Given high investor and consumer interest in the microbiome in the USA and growing sales the board OptiBiotix has commissioned advisors to explore the potential of a dual NASDAQ listing," said chief executive Stephen O’Hara.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health agrees exclusive deal for LPLDL in USA and Canada

Steve Prescott, the chief executive of ProBiotix, which is a wholly-owned subsidiary of OptiBiotix Health PLC (LON:OPTI), caught up for a brief chat with Proactive London's Andrew Scott after announcing they've signed a distributor agreement with Advanced NutriSolutions Inc./Select Ingredient...

1 week, 4 days ago

2 min read